Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine Melbourne, Australia, 9 April 2025 – ENA Respiratory, a clinical-stage pharmaceutical company […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-04-09 08:26:102025-04-09 08:26:10ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-04-02 07:39:382025-04-02 07:39:38ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-02-10 08:01:272025-02-10 08:01:27ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-28 03:25:282025-01-28 08:07:34ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-22 05:00:512025-01-22 08:18:42ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 18 December 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2024-12-18 07:26:472024-12-18 07:26:47ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine Melbourne, Australia, 9 April 2025 – ENA Respiratory, a clinical-stage pharmaceutical company […]
ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in […]
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]
ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]
ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 18 December 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]